DVAX
Price
$10.72
Change
+$0.06 (+0.56%)
Updated
Jul 18, 04:59 PM (EDT)
Capitalization
1.62B
13 days until earnings call
TAK
Price
$14.43
Change
-$0.31 (-2.10%)
Updated
Jul 18, 04:59 PM (EDT)
Capitalization
43.11B
12 days until earnings call
Interact to see
Advertisement

DVAX vs TAK

Header iconDVAX vs TAK Comparison
Open Charts DVAX vs TAKBanner chart's image
Dynavax Technologies
Price$10.72
Change+$0.06 (+0.56%)
Volume$15.18K
Capitalization1.62B
Takeda Pharmaceutical
Price$14.43
Change-$0.31 (-2.10%)
Volume$48.83K
Capitalization43.11B
DVAX vs TAK Comparison Chart in %
Loading...
DVAX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TAK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
DVAX vs. TAK commentary
Jul 18, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DVAX is a Hold and TAK is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 18, 2025
Stock price -- (DVAX: $10.67 vs. TAK: $14.74)
Brand notoriety: DVAX and TAK are both not notable
Both companies represent the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: DVAX: 48% vs. TAK: 144%
Market capitalization -- DVAX: $1.62B vs. TAK: $43.11B
DVAX [@Pharmaceuticals: Other] is valued at $1.62B. TAK’s [@Pharmaceuticals: Other] market capitalization is $43.11B. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $77.48B to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $3.81B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DVAX’s FA Score shows that 0 FA rating(s) are green whileTAK’s FA Score has 2 green FA rating(s).

  • DVAX’s FA Score: 0 green, 5 red.
  • TAK’s FA Score: 2 green, 3 red.
According to our system of comparison, TAK is a better buy in the long-term than DVAX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DVAX’s TA Score shows that 5 TA indicator(s) are bullish while TAK’s TA Score has 3 bullish TA indicator(s).

  • DVAX’s TA Score: 5 bullish, 4 bearish.
  • TAK’s TA Score: 3 bullish, 4 bearish.
According to our system of comparison, DVAX is a better buy in the short-term than TAK.

Price Growth

DVAX (@Pharmaceuticals: Other) experienced а -2.11% price change this week, while TAK (@Pharmaceuticals: Other) price change was -0.67% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +0.74%. For the same industry, the average monthly price growth was +5.79%, and the average quarterly price growth was +72.07%.

Reported Earning Dates

DVAX is expected to report earnings on Oct 30, 2025.

TAK is expected to report earnings on Oct 30, 2025.

Industries' Descriptions

@Pharmaceuticals: Other (+0.74% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
TAK($43.1B) has a higher market cap than DVAX($1.62B). TAK has higher P/E ratio than DVAX: TAK (36.79) vs DVAX (31.63). TAK YTD gains are higher at: 11.329 vs. DVAX (-16.445). TAK has higher annual earnings (EBITDA): 1.01T vs. DVAX (9.67M). TAK has more cash in the bank: 317B vs. DVAX (742M). DVAX has less debt than TAK: DVAX (257M) vs TAK (4.66T). TAK has higher revenues than DVAX: TAK (4.17T) vs DVAX (232M).
DVAXTAKDVAX / TAK
Capitalization1.62B43.1B4%
EBITDA9.67M1.01T0%
Gain YTD-16.44511.329-145%
P/E Ratio31.6336.7986%
Revenue232M4.17T0%
Total Cash742M317B0%
Total Debt257M4.66T0%
FUNDAMENTALS RATINGS
DVAX vs TAK: Fundamental Ratings
DVAX
TAK
OUTLOOK RATING
1..100
955
VALUATION
overvalued / fair valued / undervalued
1..100
67
Overvalued
10
Undervalued
PROFIT vs RISK RATING
1..100
74100
SMR RATING
1..100
9385
PRICE GROWTH RATING
1..100
5854
P/E GROWTH RATING
1..100
9718
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TAK's Valuation (10) in the Pharmaceuticals Major industry is somewhat better than the same rating for DVAX (67) in the Biotechnology industry. This means that TAK’s stock grew somewhat faster than DVAX’s over the last 12 months.

DVAX's Profit vs Risk Rating (74) in the Biotechnology industry is in the same range as TAK (100) in the Pharmaceuticals Major industry. This means that DVAX’s stock grew similarly to TAK’s over the last 12 months.

TAK's SMR Rating (85) in the Pharmaceuticals Major industry is in the same range as DVAX (93) in the Biotechnology industry. This means that TAK’s stock grew similarly to DVAX’s over the last 12 months.

TAK's Price Growth Rating (54) in the Pharmaceuticals Major industry is in the same range as DVAX (58) in the Biotechnology industry. This means that TAK’s stock grew similarly to DVAX’s over the last 12 months.

TAK's P/E Growth Rating (18) in the Pharmaceuticals Major industry is significantly better than the same rating for DVAX (97) in the Biotechnology industry. This means that TAK’s stock grew significantly faster than DVAX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
DVAXTAK
RSI
ODDS (%)
Bearish Trend 2 days ago
79%
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
75%
Bullish Trend 2 days ago
46%
Momentum
ODDS (%)
Bullish Trend 2 days ago
75%
Bearish Trend 2 days ago
48%
MACD
ODDS (%)
N/A
Bearish Trend 2 days ago
43%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
77%
Bearish Trend 2 days ago
49%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
73%
Bearish Trend 2 days ago
42%
Advances
ODDS (%)
Bullish Trend 9 days ago
74%
Bullish Trend 19 days ago
43%
Declines
ODDS (%)
Bearish Trend 26 days ago
80%
Bearish Trend 3 days ago
45%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
85%
N/A
Aroon
ODDS (%)
Bullish Trend 2 days ago
75%
Bullish Trend 2 days ago
41%
View a ticker or compare two or three
Interact to see
Advertisement
DVAX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TAK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
BBP62.660.45
+0.72%
Virtus LifeSci Biotech Products ETF
CNRG64.810.38
+0.59%
SPDR® Kensho Clean Power ETF
DNP9.740.04
+0.41%
DNP Select Income Fund
EVLU28.06-0.11
-0.37%
iShares MSCI Emerging Mkts Val Fac ETF
ISD14.05-0.09
-0.64%
PGIM High Yield